培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究

目的：探讨培美曲塞联合顺铂与吉西他滨联合顺铂治疗初治晚期非小细胞肺癌的安全性和临床有效性。方法选取我院2008年1月～2013年5月收治的64例晚期非小细胞肺癌患者进行分析研究，随机分为两组，每组32例，A 组采用培美曲塞联合顺铂进行治疗，B 组采用吉西他滨联合顺铂进行治疗。观察两组患者临床治疗效果与不良反应。结果 A 组患者治疗总有效率为28.13％，疾病控制率为78.13％；B 组患者治疗总有效率为21.87％，疾病控制率为68.75％，差异无统计学意义（P ＞0.05）。A 组患者在躯体功能、心理功能、社会功能、物质生活等各项生活质量指标上都要高于 B 组，但两组比较差异无统计学意义（P ＞0.05）。结论培美曲塞联合顺铂比吉西他滨联合顺铂治疗初治晚期非小细胞肺癌的疗效要好，且安全性高、毒副作用较小，值得临床推广应用。

Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer

Objective To study the efficacy and toxicity of pemetrexed combined with cisplatin and gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Chosen 64 patients in our hospital from January 2008 to May 2008 with locally advanced or metastatic NSCLC were enrolled into the study, divided them into two groups, 32 cases in each group, group A was treated with pemetrexed combined with cisplatin, group B treated by gemcitabine combined with cisplatin. The efficacy was observed and compared between two groups. Results The total clinical effective rates in group A is 28.13%, the disease control rates is 78.13% ; and group B is 21.87% , disease control rates at 68.75% , was statistically non-significant （P 〉 0.05）. Compared with the group B patients, the body function, psychological function, social function and material life in group A is higher than group B, but there have no significant difference（P 〉 0.05）. Conclusion Pemetrexed plus cisplatin had an advantage than gemcitabine plus cisplatin in treatment of advanced non-small cell lung cancer, and high safety, less side effects. It is worth popularizing application in clinic.